Discovery and validation of autosomal dominant Alzheimer's disease mutations.

Autor: Hsu S; Department of Psychiatry, Washington University School of Medicine, 425 S. Euclid Ave, Campus Box 8134, St. Louis, MO, 63110, USA., Gordon BA; Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA., Hornbeck R; Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA., Norton JB; Department of Psychiatry, Washington University School of Medicine, 425 S. Euclid Ave, Campus Box 8134, St. Louis, MO, 63110, USA., Levitch D; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Louden A; Department of Psychiatry, Washington University School of Medicine, 425 S. Euclid Ave, Campus Box 8134, St. Louis, MO, 63110, USA., Ziegemeier E; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Laforce R Jr; Clinique Interdisciplinaire de Mémoire du CHU de Québec, Département des Sciences Neurologiques, Faculté de Médecine, Université Laval, Québec City, Québec, Canada., Chhatwal J; Massachusetts General Hospital/Martinos Center for Biomedical Imaging, 149 13th Street, Gerontology Research Room 2669, Charlestown, MA, 02129, USA., Day GS; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., McDade E; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Morris JC; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Fagan AM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Benzinger TLS; Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA., Goate AM; Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA., Cruchaga C; Department of Psychiatry, Washington University School of Medicine, 425 S. Euclid Ave, Campus Box 8134, St. Louis, MO, 63110, USA., Bateman RJ; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Karch CM; Department of Psychiatry, Washington University School of Medicine, 425 S. Euclid Ave, Campus Box 8134, St. Louis, MO, 63110, USA. karchc@wustl.edu.
Jazyk: angličtina
Zdroj: Alzheimer's research & therapy [Alzheimers Res Ther] 2018 Jul 18; Vol. 10 (1), pp. 67. Date of Electronic Publication: 2018 Jul 18.
DOI: 10.1186/s13195-018-0392-9
Abstrakt: Background: Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes.
Methods: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses.
Results: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379_382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity.
Conclusions: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje